Since earning his Bachelor’s degree from Northern Illinois University and his MBA from DePaul University, Jeff Aronin has been running at full steam ever since. What follows is a recap of an article about Jeff on Live Newspaper’s website.
Early on in his working life, Jeff was shadowing a doctor as the physician visited patients. One patient was a boy with frequent, ongoing seizures. Instead of defaulting to surgery, the physician decided to try drug therapy first. That was the beginning of Jeff Aronin’s fascination and respect for the power of pharmaceutical medicine. Jeff decided then and there to apply his considerable business knowledge to the creation of more effective drugs.
In 2000 Jeff Aronin founded the pharmaceutical startup Ovation Pharmaceuticals. Jeff’s approach was straightforward: Identify a patient need, next find science holding the promise of treatment, and then assemble, direct, and motivate a team to bring it to market efficiently. Just nine years later, Ovation sold to Lundbeck for $900-million. Lundbeck opted to keep Jeff on as CEO, thus avoiding any stumbles during the transition.
Jeff’s leadership qualities appear to be readily recognizable, as he has served as CEO of several health-sciences companies, among them: Harmony BioSciences, Castle Creek Pharmaceuticals, and Paragon Pharmaceuticals. Along the way, Jeff and his teams have gotten 13 new drugs approved — a remarkable feat in the drug industry.
Jeff Aronin is committed to growing the biotech industry in Chicago. Jeff founded the Chicago biotech incubator Matter, which currently has over 200 startups in development. Jeff enjoys sharing his experience, insights, and vision with budding entrepreneurs.
Jeff has spent the last decade at Paragon in the capacities of Chairman and CEO. Jeff’s rare combination of scientific vision, business acumen, and a focus on finding treatments for patients suffering from rare diseases has made Jeff a recognized leader in the industry.
Jorge Moll is a revered scientist known for documenting multiple clinical studies on how the human brain functions. Over the past years, he has conducted research on neurology and the physical mechanisms encompassing emotional responses including the ways through which mental illnesses impact the dominance a human’s brain. Following the research results from 2006, Moll has vested his research in addressing the architecture of the human brain and how it can affect the manner in which a person is touched to give back to the community.
Perhaps there is a relationship between giving back and the functioning of the human brain. Even better, Moll’s study seeks to decipher these facts by saying that a human’s capacity to engage in social causes is related to the cost benefit. Moreover, monetary donations sent to charities make good examples of how the human brain is affected. He calls in an altruistic behaviour because the structure of the human brain is one distinct aspect in the body. As such, it makes one wonder how exactly the physical composition of a brain affects the thinking capacity of an individual.
In an interview, Jorge Moll, joined by his team of qualified neuroscientists answered a few questions in regards to the human brain and donations. The study sought to analyse the subjects and emphasise their character when subjected to series of questions regarding the altruistic nature of the brain. As such, researchers emphasised that the mesolimbic system controls the part of the brain that feels the need to be generous with people. This is done through the release of a chemical component called dopamine. Over the course of this study, candidates were asked to either oppose or support the claims. It was later concluded that people who have been through difficult situations are more inclined to give back to the society because of the response from the brain.
Describing Jorge Moll
Jorge Moll is a qualified medical professional from The Federal University of Rio De Janeiro. He completed his residency from the same school and headed out to receive his Ph.D from the Sao Paulo University.